RIA Advisory Group LLC Acquires 492 Shares of Amgen Inc. (NASDAQ:AMGN)

RIA Advisory Group LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,128 shares of the medical research company’s stock after acquiring an additional 492 shares during the quarter. Amgen comprises 0.5% of RIA Advisory Group LLC’s holdings, making the stock its 28th largest holding. RIA Advisory Group LLC’s holdings in Amgen were worth $1,765,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Southland Equity Partners LLC increased its position in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after purchasing an additional 34 shares during the last quarter. Acropolis Investment Management LLC boosted its holdings in Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after acquiring an additional 34 shares during the period. Opal Wealth Advisors LLC boosted its holdings in Amgen by 1.9% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after acquiring an additional 34 shares during the period. Marino Stram & Associates LLC boosted its holdings in Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after acquiring an additional 34 shares during the period. Finally, FORVIS Wealth Advisors LLC boosted its holdings in Amgen by 1.4% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock valued at $743,000 after acquiring an additional 35 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. The Goldman Sachs Group upped their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Raymond James assumed coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating on the stock. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and upped their price target for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, Truist Financial restated a “buy” rating and set a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Stock Up 2.4 %

AMGN traded up $6.18 on Friday, hitting $268.93. The company had a trading volume of 3,375,252 shares, compared to its average volume of 2,858,855. The stock has a fifty day moving average price of $277.34 and a 200-day moving average price of $281.24. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market capitalization of $144.12 billion, a price-to-earnings ratio of 21.22, a P/E/G ratio of 2.46 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter in the previous year, the firm earned $4.09 earnings per share. The company’s revenue was up 19.8% on a year-over-year basis. Analysts predict that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.